Unknown

Dataset Information

0

Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies.


ABSTRACT: Antibodies against coronavirus spike protein potently protect against infection and disease, but whether such protection can be extended to variant coronaviruses is unclear. This is exemplified by a set of iconic and well-characterized monoclonal antibodies developed after the 2003 SARS outbreak, including mAbs m396, CR3022, CR3014 and 80R, which potently neutralize SARS-CoV-1, but not SARS-CoV-2. Here, we explore antibody engineering strategies to change and broaden their specificity, enabling nanomolar binding and potent neutralization of SARS-CoV-2. Intriguingly, while many of the matured clones maintained specificity of the parental antibody, new specificities were also observed, which was further confirmed by X-ray crystallography and cryo-electron microscopy, indicating that a limited set of VH antibody domains can give rise to variants targeting diverse epitopes, when paired with a diverse VL repertoire. Our findings open up over 15 years of antibody development efforts against SARS-CoV-1 to the SARS-CoV-2 field and outline general principles for the maturation of antibody specificity against emerging viruses.

SUBMITTER: Rouet R 

PROVIDER: S-EPMC8158043 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| EGAS00001004412 | EGA
| S-EPMC7301900 | biostudies-literature
| S-EPMC7591918 | biostudies-literature
| S-SCDT-EMBOR-2021-53956-T | biostudies-other
| S-EPMC8653362 | biostudies-literature
| S-EPMC9528872 | biostudies-literature
| S-BSST379 | biostudies-other
| S-EPMC8847360 | biostudies-literature
| S-EPMC1924550 | biostudies-literature
| S-EPMC9114490 | biostudies-literature